Motif Bio plc (AIM: MTFB) the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that Dr John Stakes III, Non-Executive Director, has resigned his position on the Board with immediate effect due to ill health.
Richard Morgan, Chairman of Motif Bio, stated: “On behalf of the Board and shareholders I would like to thank John for his contribution to Motif Bio and his valuable support as we’ve made significant progress in the development of our lead compound iclaprim. John was a director of Motif BioSciences Inc for several years prior to joining the board of Motif Bio plc at the time of the admission to AIM in April last year, and his clinical knowledge as well as his experience in corporate governance have been great assets to the Company. We wish John the very best and thank him for all of his support.”
For further information please contact:
Motif Bio plc
Richard Morgan (Chairman)
Graham Lumsden (Chief Executive Officer)
info@motifbio.com
Zeus Capital Limited (NOMAD & BROKER)
Phil Walker/Giles Balleny
Dominic Wilson
+44 (0)20 3829 5000
Northland Capital Partners Limited (BROKER)
Patrick Claridge/ David Hignell
John Howes/ Rob Rees (Broking)
+44 (0)20 7382 1100
Walbrook PR Ltd. (FINANCIAL PR & IR)
Paul McManus
Mike Wort
+44 (0)20 7933 8780 or motifbio@walbrookpr.com
Mob: +44 (0)7980 541 893
Mob: +44 (0)7900 608 002
MC Services AG (EUROPEAN IR)
Raimund Gabriel +49 (0)89 210 2280
About Motif Bio (www.motifbio.com)
Motif is a clinical-stage biopharmaceutical company, specialising in the development of novel antibiotics that are designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. Our lead product candidate, iclaprim, is being developed for the treatment of the most common and serious bacterial infections such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains such as MRSA (methicillin-resistant Staphylococcus aureus). Two Phase III ABSSSI clinical trials are on track to be completed in 2H17 and if approved, iclaprim could be ready for commercialisation in 2018.
The Company is in discussions with pharmaceutical companies and universities to build a pipeline of innovative antibiotics targeting Gram-positive and Gram-negative bacteria.
